Changes in: - accounts receivable(1,285,806)46,577 - inventories(1,319,475)(2,281,688) - income tax payable 12,210(103,393) - prepaid expenses and deposits782,156(9,231)- deferred revenue (99,517)(302,680) - accounts payable and accrued liabilities(3,404,810)(2,878,114)Net cash used in by operating activities(11,868,253)(7,689,738)Cash flows from (used in) financing activities- Loan proceeds2,023,939-- Proceeds from shares subscribed 3,040-- Exercise of stock options47,360284,709- Dividends paid to non-controlling shareholder of Sinovac Beijing(800,717)(2,456,884)- Loan from non-controlling shareholder of Sinovac Dalian3,175,266-Net cash provided by (used in) financing activities4,448,888(2,172,175)Cash flows used in investing activities - Prepayments for acquisition of equipment-(1,529) - Acquisition of property, plant and equipment(2,960,461)(1,153,348)Net cash provided used in investing activities(2,960,461)(1,154,877)Exchange gain on cash and cash equivalents582,778407,599Decrease in cash and cash equivalents(9,797,048)(10,609,191)Cash and cash equivalents, beginning of period104,286,695101,585,490Cash and cash equivalents, end of period$
90,976,299Supplemental disclosure of cash flow information:Cash paid for interest,net of amounts capitalized
103,393Cash paid for income taxes
306,017Supplemental schedule of non-cash activities:Acquisition of property, plant and equipment included in accounts payable and accrued liabilities
|SOURCE Sinovac Biotech Ltd.|
Copyright©2010 PR Newswire.
All rights reserved